Printer Friendly

Prevalence of Non-O157:H7 Shiga Toxin-Producing Escherichia coli in Diarrheal Stool Samples from Nebraska.

We determined the prevalence of Shiga toxin-producing Escherichia coli (STEC) in diarrheal stool samples from Nebraska by three methods: cefixime-tellurite sorbitol MacConkey (CT-SMAC) culture, enterohemorrhagic E. coil (EHEC) enzyme immunoassay, and [stx.sub.1,2] polymerase chain reaction (PCR). Fourteen (4.2%) of 335 specimens were positive by at least one method (CT-SMAC culture [6 of 14], EHEC enzyme immunoassay [13 of 14], [stx.sub.1,2], PCR [14 of 14]). Six contained serogroup 0157, while non-0157 were as prevalent as 0157 serogroups.

Disease caused by Shiga toxin-producing Escherichia coli (STEC) ranges from self-limiting diarrhea to hemorrhagic colitis and hemolytic uremic syndrome (HUS). Serotype O157:H7, the most frequently implicated STEC causing hemorrhagic colitis and HUS, has been isolated from large foodborne outbreaks, as well as sporadic cases, in North America and abroad. However, 60 STEC serotypes have been implicated in diarrheal disease, and several non-O157:H7 serotypes have been implicated as the cause of foodborne outbreaks and HUS in the United States, Europe, and Australia. Studies from Canada, Europe, Argentina, and Australia suggest that nonO157:H7 STEC infections are as prevalent, or more so, than O157:H7 infections.

E. coli O157:H7 is easily differentiated from other E. coli by its inability to rapidly ferment sorbitol; however, non-O157:H7 STEC are phenotypically similar to commensal nonpathogenic E. coli and are not detected with sorbitol MacConkey agar. To detect non-O157:H7 STEC, nonculture methods are used (enzyme immunoassay [EIA] or polymerase chain reaction [PCR]), which are typically only performed in reference laboratories. The purpose of this study was to determine the prevalence of non-O157:H7 STEC in persons with diarrhea in Nebraska.

The Study

Nine regional clinical microbiology laboratories in Nebraska sent stool samples from March 1, 1998, to October 31, 1998, to the Nebraska Public Health Laboratory, University of Nebraska Medical Center. All stool samples that were sent to a participating laboratory with a physician's order to screen for enteric pathogens were included. Thus, all samples were from patients with a differential diagnosis of bacterial gastroenteritis. Patients who had been in the hospital for [is greater than] 2 days before diarrhea developed were excluded. The samples were added to a Para-Pak C&S stool transport container (Meridian Diagnostics, Cincinnati, OH) and sent by courier to the Nebraska Public Health Laboratory.

Samples were plated to cefixime-tellurite sorbitol MacConkey (CT-SMAC) agar plates and screened for typical sorbitol-negative colonies (1). Presumptive colonies were identified as E. coli by API strips (Biomerieux Vitek, Hazelwood, MO) and serotyped with RIM E. coli O157:H7 (Remel, Lenexa, KS). Samples were injected into 10 mL MacConkey broth (Difco, Detroit, MI) and incubated overnight at 37 [degrees] C. The Premier enterohemorrhagic E. coli (EHEC) assay was performed by using 50 [micro]L of overnight growth. The reaction mixtures were read spectrophotometrically at 450 nm and scored as positive or negative. PCR was performed by first extracting DNA from the overnight culture of MacConkey broth using a QIAamp Tissue kit (Qiagen, Santa Clarita, CA). The following set of primers, which detects both [stx.sub.1] and [stx.sub.2], was used: 5'TTTACG ATAGACTTCTCGAC3' and 5'CACATATAA TTA TTTCGCTC3' (2). E. coli O157:H7 strain G5244 was used as positive control (Centers for Disease Control and Prevention [CDC] strain collection). Samples Shiga-toxin positive by either EHEC enzyme EIA, PCR, or both were plated onto sheep-blood agar (Remel) and streaked for isolation. After overnight growth, multiple E. coli-like colonies were selected for retesting by using the Premier EHEC assay. Positive colonies were identified to species level by using API strips and serotyped by CDC.

Multiplex PCR (3) was performed on isolated Shiga toxin-positive colonies to detect specific genes encoding Shiga toxins 1 and 2 ([stx.sub.1] and [stx.sub.2]), intimin (eaeA), and enterohemolysin A (ehxA). Genomic DNA suitable for pulsed-field gel electrophoresis (PFGE) was prepared (4) and digested with XbaI (Roche, Indianapolis, IN). E. coli O157:H7 G5244 was used as a standard. PFGE patterns were captured by a Bio-Rad Gel-Doc system and were analyzed by Molecular Analyst software (Bio-Rad, Hercules, CA).

Of the nine clinical laboratories that submitted 335 samples during the study period, five submitted samples positive by CT-SMAC culture, EIA, or stx PCR (Table 1). Fourteen 4.2%) samples were positive by at least one of the methods; 13 of these were obtained either through direct culture by using CT-SMAC or through Shiga toxin screening and subsequent colony isolation. Six of the thirteen were serotype O157:H7 or O157:NM; seven were non-O157 serotypes. All seven of the non-O157 isolates were the predominant species found in the culture when the sample was plated on sheep-blood agar. All six E. coli O157:H7 or O157:NM isolates were detected by using CT-SMAC culture and stx PCR; five of six were detected by EIA. All of seven non-O157 isolates were detected by EIA or stx PCR. One sample (isolate B3) that was negative by EIA but positive by PCR and CT-SMAC culture was subsequently found to be positive by EIA when tested individually. One sample from laboratory C was positive for EIA and stx PCR (both tests were weak positives), but no Shiga toxin-positive colony was obtained upon repeat subculture. The low prevalence of this organism in the stool sample may reflect STEC carriage in this patient. By the combined results of both culture and EIA as the reference standard (14 samples positive, 321 samples negative), the sensitivity and specificity of the stx PCR (14 samples positive, 321 samples negative) were each 100%.

Table 1. Results of CT-SMAC culture, enzyme immunoassay, and stx polymerase chain reaction
Laboratory Isolate Serotype SMAC(a) EIA PCR

A A1 O157:H7 + + +
 A2 O157:H7 + + +
 A3 O26:H11 - + +
 A4 O157:NM + + +
B B1 O145:NM - + +
 B2 O103:H2 - + +
 B3 O157:NM + - +
C NI(b) NI - + +
D D1 O111:NM - + +
 D2 O111:NM - + +
 D3 O157:H7 + + +
 D4 O157:H7 + + +
E E1 Orough:H2 - + +
 E2 O26:H11 - + +

(a) (+) Denotes a positive CT-SMAC culture, EIA, or stx PCR; (-) denotes a negative CT-SMAC culture, EIA, or stx PCR; CT-SMAC = cefixime-tellurite sorbitol MacConkey agar; EIA = enzyme immunoassay; PCR = polymerase chain reaction.

(b) NI = Not isolated.

PCR was performed on the 13 isolated STEC to detect [stx.sub.1], [stx.sub.2], eae, and ehxA (Table 2). All isolates, regardless of serotype, encoded eae and ehxA; three of five O157 isolates encoded both [stx.sub.1] and [stx.sub.2]; two of seven non-O157:H7 isolates encoded [stx.sub.2] (both O111:NM). PFGE showed that all but two STEC isolates were unrelated; isolates D1 and D2 (both O111:NM), which were isolated from samples sent from the same laboratory, were indistinguishable (data not shown).

Table 2. Results from multiplex polymerase chain reaction (PCR) amplification
Isolate Serotype stx1(a) stx2 eae ehxA

A1 O157:H7 + + + +
A2 O157:H7 - + + +
A3 O26:H11 + - + +
A4 O157:NM + + + +
B1 O145:NM + - + +
B2 O103:H2 + - + +
D1 O111:NM + + + +
D2 O111:NM + + + +
D3 O157:H7 - + + +
D4 O157:H7 + + + +
E1 Orough:H2 + - + +
E2 O26:H11 + - + +

(a) (+) Denotes presence of gene as assessed by PCR; (-) denotes absence of gene as assessed by PCR.


In a 1997 study of 30,000 diarrheal stool samples, E. coli O157:H7 was the fourth most prevalent bacterial enteric pathogen (5). However, the incidence of non-O157 STEC in the United States is not well established. Studies from Europe have shown that the prevalence of STEC in diarrheal samples is 0.3% to 9.3%; serogroup O157 prevalence is 0% to 2.7%. In Australia, serotype O111:NM is the most frequent cause of serious human disease and has been associated with outbreaks. In a recent study of 3,289 diarrheal samples from clinical laboratories in the United States, non-O157 STEC were more prevalent than O157 serotypes (6). STEC was found to be as prevalent (1.2%) as Shigella sp. (1.4%), and almost as prevalent as Salmonella sp. (2.4%) and Campylobacter sp. (2.0%). Testing for E. coli O157:H7 alone would have missed up to 50% of STEC.

Our study is the first to address the prevalence of non-O157 STEC in diarrheal samples from the Great Plains region of the northern United States, where cattle and other animal reservoirs of STEC are abundant. In our study, 4.2% of the samples were positive for STEC by CT-SMAC culture, PCR, or Meridian EHEC EIA. Though this prevalence is higher than previously reported in the United States, other studies have shown that northern states have a higher prevalence of E. coli O157:H7 (7). In addition, Nebraska has a large rural population, whose members may have contact with animal reservoirs that carry STEC. Five different non-O157 STEC serotypes were isolated: O111:NM, O26:H11, O145:NM, O103:H2, and Orough:H2. Four of these are associated with HUS (O111:NM [8-10], O26:H11[11], O145:NM [12], and O103:H2 [13]). In addition, serotypes O111:NM and O26:H11 have been associated with diarrhea in weaned calves (14). Although most STEC cases are linked to eating undercooked hamburger (15), contact with food animals has also been implicated as a source of infection (16).

Shiga toxins 1 and 2 are the main virulence factors associated with hemorrhagic colitis and HUS, presumably because they interact with endothelial cells at the site of infection and in the glomeruli and arterioles of the kidney (17). [stx.sub.1] and [stx.sub.2] are highly related yet immunologically distinct. STEC produce other accessory virulence factors, including intimin (eae) and enterohemolysin A (ehxA). The former is responsible for the characteristic histopathologic feature known as the attaching and effacing (A/E) lesion (18); ehxA is a hemolysin encoded by the 90-kb virulence-associated plasmid found in most STEC infecting humans (19). A study of 237 isolates from 118 serotypes found a significant association between [stx.sub.2] and eae in isolates that caused hemorrhagic colitis and HUS in humans (20) and between ehxA and severe disease. STEC isolates from asymptomatic human carriers usually do not encode eae and therefore may not have a mechanism to adhere to intestinal epithelial cells (21). However, STEC isolates lacking the eae gene have been associated with hemorrhagic colitis and HUS (22). All STEC isolates obtained in this study encoded both eae and ehxA. The six O157 isolates also encoded [stx.sub.2], as did both O111:NM isolates, which indicates that at least these eight isolates could produce serious disease. Five of seven non-O157 isolates encoded [stx.sub.1] only; however, STEC isolates associated with hemorrhagic colitis and HUS that encoded only [stx.sub.1] have been reported (23).

All O157:H7, O157:NM, and O26:Hll isolates in our study were distinct by PFGE RFLP patterns, which suggests that these cases were sporadic. However, two O111:NM isolates (D1 and D2) from the same community had indistinguishable PFGE RFLP patterns. The isolates were from different patients and were cultured within 1 day of each other. This suggests that an outbreak of O111:NM may have occurred that was not detected by standard laboratory techniques. However, without epidemiologic information, these results are difficult to interpret.

This study demonstrated that non-O157 STEC serotypes are at least as prevalent as serogroup O157 in diarrheal samples from Nebraska. Non-O157 STEC isolates presumably were the cause of diarrhea in 7 of 14 positive samples. These non-O157 isolates carried known STEC virulence genes and were the predominant organism found in culture. Other bacterial pathogens such as Salmonella, Shigella, and Campylobacter were not isolated from these seven samples. Our results suggest that stx PCR is as sensitive and specific as CT-SMAC culture and EIA combined, and therefore may be used as an alternate method to diagnose diarrheal infections caused by STEC. Clinical laboratories may need to implement serotype-independent methods to avoid underdiagnosis of STEC-mediated bacterial gastroenteritis.


(1.) Zadik PM, Chapman PA, Siddons CA. Use of tellurite for the selection of verocytotoxigenic Escherichia coli O157. J Med Microbiol 1993;39:155-8.

(2.) Fratamico PM, Sackitey SK, Wiedmann M, Deng MY. Detection of Escherichia coli O157:H7 by multiplex PCR. J Clin Microbiol 1995;33:2188-91.

(3.) Fagan PK, Hornitzky MA, Bettelheim KA, Djordjevic SP. Detection of Shiga-like toxin ([stx.sub.1] and [stx.sub.2]), intimin (eaeA), and enterohemorrhagicEscherichia coli (EHEC) hemolysin (EHEC hlyA) genes in animal feces by multiplex PCR. Appl Environ Microbio11999;65:868-72.

(4.) Gautom RK. Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day. J Clin Microbiol 1997;35:2977-80.

(5.) Slutsker L, Ries AA, Greene KD, Wells JG, Hutwagner L, Griffin PM, et al. Escherichia coli O157:H7 diarrhea in the US: clinical and epidemiological features. Aan Intern Med 1997; 126:505-13.

(6.) Acheson DW, Frankson K, Willis D, STEC Prevalence Study Group. Multicenter prevalence study of Shiga toxin-producing Escherichia coli. Abstracts of the 98th General Meeting for the American Society for Microbiology. Washington: American Society for Microbiology; 1998. [Abstract C-205]

(7.) Griffin PM. Escherichia coli O157:H7 and other enterohemorrhagic Escherichia coli. In: Blaser MJ, Smith PD, Raudin JI, Greenburg HB, Guerrant RL, editors. Infections of the gastrointestinal tract. New York: Raven Press; 1995. p. 739-61.

(8.) Boudaillez B, Berquin P, Mariani-Kurkdjian P, Bef D, Cuvelier B, Capek I, et al. Possible person to person transmission of Escherichia coli O111-associated hemolytic uremic syndrome. Pediatr Nephrol 1996; 11:36-9.

(9.) Caprioli A, Luzzi I, Rosmini F, Resti C, Edefonti A, Perfumo F, et al. Community-wide outbreak of hemolytic-uremic syndrome associated with non-O157 verotoxin-producing Escherichia coli. J Infect Dis 1994; 169:208-11.

(10.) Robbins-Browne RM, Elliott E, Desmarchelier P. Shiga toxin-producing Escherichia coli in Australia. In: Kapar JP, O'Brien AD, editors. Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. Washington: American Society for Microbiology; 1998. p.66-72.

(11.) Sramkova LM, Bielaszewska M, Janda J, Blahova K, Hausner O. Vero cyctotoxin-producing strains of Escherichia coli in children with hemolytic uremic syndrome and diarrhoea in Czechoslovakia. Infection 1990; 18:204-9.

(12.) Karmali MA, Petric M, Lim C, Fleming PC, Arus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151:775-82.

(13.) Tarr PI, Fouser LS, Stapleton AE, Wilson RA, Kim HH, Vary JC Jr, et al. Hemolytic uremic syndrome in a six-year-old girl after a urinary tract infection with Shiga toxin-producing Escherichia coli O103:H2. N Engl J Med 1996;335:635-8.

(14.) Kudva IT, Hatfield PG, Hovde CJ. Characterization of Escherichia coli O157:H7 and other Shiga toxin-producing Escherichia coli serotypes isolated from sheep. J Clin Microbiol 1997;35:892-9.

(15.) Slutsker L, Ries AA, Maloney K, Wells JG, Greene KD, Griffin PM, et al. A nationwide case-control study of E. coli O157:H7 infection in the United States. J Infect Dis 1998; 177:962-6.

(16.) Trevena WB, Willshaw GA, Cheasty T, Wray C. Associations between humem infection with vero cytotoxin-producing Escherichia coli O157:H7 and farm animal contact. In: Proceedings of the 3rd international symposium and workshop on Shiga-toxin (verocytotoxin)-producing Escherichia coli infections. 1997. abstract V28/I.

(17.) Kaplan BS, Cleary TG, Obrig TG. Recent advances in understanding the pathogenesis of the hemolytic uremic syndrome. Pediatr Nephrol 1990;4:276-83.

(18.) McDaniel TK, Kaper JB. A cloned pathogenicity island from enteropathogenic Escherichia coli confers the attaching and effacing phenotype of E. coli K-12. Mol Microbiol 1997;23:399-407.

(19.) Boerlin P, Chen S, Colbourne JK, Johnson R, De Grandis S, Gyles C. Evolution of enterohemorrhagic Escherichia coli hemolysin plasmids and the

locus for enterocyte effacement in Shiga toxin-producing Escherichia coli. Infect Immun 1998;66:2553-61.

(20.) Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, Gyles CL. Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol 1999;37:497-503.

(21.) Stephen R, Untermann F. Virulence factors and phenotypical traits ofverotoxin-producing Escherichia coli strains isolated from asymptomatic human carriers. J Clin Microbiol 1999;37:1570-2.

(22.) Paton AW, Woodrow MC, Doyle RW, Lanser JA, Paton JC. Molecular characterization of Shiga toxigenic Escherichia coli O113:H21 strain lacking eae responsible for a cluster of cases of HUS. J Clin Microbiol 1999;37:3357-61.

(23.) Beutin L, Zimmermann S, Gleier K. Human infections with Shiga toxin-producing Escherichia coli other than serogroup O157 in Germany. Emerg Infect Dis 1998;4:635-9.

Address for correspondence: Paul D. Fey, University of Nebraska Medical Center, Nebraska Public Health Laboratory, 985400 Nebraska Medical Center, Omaha, NE 681985400, USA; fax: 402-559-5581; e-mail:

Paul D. Fey,(*) R.S. Wickert,(*) M.E. Rupp, T.J. Safranek,([dagger]) and S.H. Hinrichs(*)

(*) University of Nebraska Medical Center, Omaha, Nebraska, USA; ([dagger]) Department of Health and Human Services, Lincoln, Nebraska, USA

Dr. Fey is an assistant professor in infectious disease and pathology and microbiology and the associate director of the Nebraska Public Health Laboratory at the University of Nebraska Medical Center. His interests include the epidemiology and antibiotic resistance of diarrheal pathogens as well as the genetics and pathogenesis of staphylococci.
COPYRIGHT 2000 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Author:Hinrichs, S.H.
Publication:Emerging Infectious Diseases
Geographic Code:1U4NE
Date:Sep 1, 2000
Previous Article:Pertussis Infection in Fully Vaccinated Children in Day-Care Centers, Israel.
Next Article:Fecal Colonization with Vancomycin-Resistant Enterococci in Australia.

Related Articles
Factory Outbreak of Escherichia coli O157:H7 Infection in Japan.
Toxin Gene Expression by Shiga Toxin-Producing Escherichia coli: the Role of Antibiotics and the Bacterial SOS Response.
First Shiga toxin-producing Escherichia coli isolate from a patient with hemolytic uremic syndrome, Brazil. (Letters).
Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988-2000. (Dispatches).
The rabbit as a new reservoir host of enterohemorrhagic Escherichia coli.
Human Escherichia coli O157:H7 genetic marker in isolates of bovine origin.
Escherichia coli O157 cluster evaluation.
Verocytotoxin-producing Escherichia coli, Japan. 1999-2004.
Shiga-toxigenic Escherichia coli O157 in agricultural fair livestock, United States.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |